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Abstract 
Background: The onset of perimenopause is a significant life event for a woman, carrying 
with it physical, medical, psychosocial and cultural significance. An estimated 85% of women 
report recurring symptoms that occur in the transition to menopause.  
 
Objective: To determine if Osteopathic Manual Therapy delivered over four weeks is an 
effective modality for treating symptoms associated with perimenopause. 
 
Methods: Six participants experiencing perimenopausal symptoms each received four 
osteopathic treatments. Baseline and follow-up measures included the Menopause Quality 
of Life Questionnaire, the Greene Climacteric Scale and a Hot Flush Dairy in which 
participants recorded the frequency and intensity of any flushes. A follow up interview was 
also undertaken to gather information regarding their thoughts and experiences throughout 
the course of the treatments. 
 
Results: The frequency and severity of perimenopausal complaints exhibited substantial and 
rapid reductions. Changes in the physical (p < 0.005) and psychological (p = 0.007) domains 
of the Menopause Quality of Life Questionnaire, along with the somatic (p < 0.006), anxiety 
(p = 0.013) and vasomotor (p < 0.025) domains of the Greene Climacteric Scale attained 
statistical significance. Communication, Overall Wellbeing and Lack of Knowledge arose as 
the key themes following qualitative analyses of the follow up interviews.  
 
Conclusions: The results of this study indicate that Osteopathic Manual Therapy may be an 
effective modality for the reduction of perimenopausal symptoms. Further to this study, 
randomised controlled trials with greater participant numbers will help to provide more 
conclusive data about the possible benefit of this therapy for women experiencing 
perimenopausal symptoms.     
 
Key words: Complementary and alternative medicine, menopause, osteopathy, hot flushes, 
menopause symptoms. 
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Introduction to Thesis 
As women transition through the menopausal process, an estimated 85% report at least one 
symptom, most notably hot flushes (Bruce & Rymer, 2009; Dennerstein et al., 1993; 
McKinlay, 1996; Woods & Mitchell, 2005). The often severe and debilitating symptoms 
associated with menopause are reported to effect attendance, mental concentration and 
output at work, as well as influencing social life, psychological health and sense of well being 
(Ogurlu, Küçük, & Aksu, 2010). The results of the Women’s Health Initiative and the Million 
Women Study have forced health practitioners and patients alike to rethink the use of 
Hormone Replacement Therapy for perimenopausal symptoms (Northrup, 2006; Rossouw, 
Anderson, & Prentice, 2002; Sievert, 2006).  
 
A significant proportion of women are beginning to use Complementary or Alternative  
Medicines (CAMs) for alleviation of their menopausal related symptoms, believing them to 
be safer and more natural (Kessel & Kronenberg, 2004; Rees, 2006). This trend has been 
occurring despite a lack of definitive research that would suggest CAMs are an effective 
form of treatment for perimenopausal symptoms. Given the holistic principals that underpin 
osteopathy, it is arguable that the complementary nature of modality therapy may be an 
effective treatment for the often broad and variable symptoms of menopause. There has 
been only one menopausal related study completed in osteopathic medicine (Cleary & Fox, 
1994), however significant methodological downfalls render this research unreliable and 
ungeneralisable to the wider population. Thus, the purpose of the study described in this 
thesis is to determine to what extent Osteopathic Manual Therapy can reduce the common 
symptoms of perimenopause.  
 
This thesis is arranged in three main sections:  
Section 1 is a literature review that outlines the physiology of menstruation and 
menopause, the stages of menopause, the risk of early or late menopause including factors 
that may influence age at onset, symptoms, and both conventional and alternative 
treatments. Section 2 of this thesis contains a manuscript formatted for submission to the 
International Journal of Osteopathic Medicine. Section 3 (appendices) contains all other 
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relevant material supplementary to the thesis. The aim of the study reported in the 
manuscript was to determine whether Osteopathic Manual Therapy delivered over a four 
week period is an effective therapy for the treatment and management of perimenopausal 
symptoms. 
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Literature Review 
Introduction 
For some women the transition from one phase of life to another, via menopause, is an 
uneventful affair. For others, the constant daily symptoms begin to affect the quality of their 
lives and they are driven to search for some means of relief (Cleary & Fox, 1994; Rahman, 
Zainudin, & Mun, 2010). The World Health Organisation defines menopause as “the 
permanent cessation of menstruation for 12 months or more” (World Health Organisation 
Scientific Group, 1996, p. 12). Following this, women are termed postmenopausal. The time 
prior to menopause is termed perimenopause. It is during this time that women notice 
changes in the characteristics of their menstrual cycles and the onset of symptoms often 
associated with perimenopause. Globally, women begin perimenopause between 45 and 47 
years of age and menopause between 47 and 55 years of age (Bruce & Rymer, 2009; Do et 
al., 1998), however several factors are theorised to influence age at onset. In this review, 
these will be addressed with respect to the consequent health problems that can arise when 
menopause is reached outside its normal range. The symptoms associated with 
perimenopause vary considerably from woman to woman and will be discussed in relation 
to conventional treatment options available to menopausal women, particularly looking at 
the risks and benefits of Hormone Replacement Therapy (HRT). The final section of the 
review examines the limited literature surrounding treatment of perimenopausal 
complaints with Complementary and Alternative Medicines (CAMs), looking specifically at 
acupuncture, exercise therapy, bioidentical hormones and Osteopathic Manual Therapy 
(OMT).  
Physiology of the Menstrual Cycle and Menopause 
A baby girl is born with approximately 100,000,000 primordial follicles, the cellular 
progenitor of the female reproductive gamete. During childhood, half of these follicles are 
absorbed by the body and by the time menstruation begins the remaining number of 
follicles is in the order of 400,000. Throughout a woman's reproductive life, approximately 
400 antral follicles grow into mature follicles and ovulate. The remaining follicles undergo 
atresia and are reabsorbed by the body. From around 45 years of age only a small number 
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of follicles remain to be stimulated, and the production of the female sex hormones 
decreases as the number of follicles approach zero. This loss in follicular activity results in 
the phenomenon known as menopause, a normal physiological and physical change 
experienced by middle-aged women. Using age 50 as a proxy age for menopause it is 
projected that by 2030 the world population of menopausal and postmenopausal women 
will reach 1.2 billion, with 47 million new entrants each year (Hill, 1996).    
 
The normal reproductive years of the female are characterised by monthly rhythmical 
changes in the rates of hormone secretion and corresponding physical changes in the 
ovaries and other sexual organs. The ovarian changes that occur throughout the menstrual 
cycle depend completely upon the hypothalamus – pituitary – gonadal axis and the 
hormones it controls (Bray, Cragg, Macknight, & Mills, 2005; Guyton & Hall, 2006). 
Gonadotrophin Releasing Hormone (GnRH) is secreted from the hypothalamus and acts on 
the anterior pituitary gland which in turn releases Follicle Stimulating Hormone (FSH) and 
Luteinising Hormone (LH). FSH is responsible for follicle development while LH stimulates 
development of the corpus luteum. In the initial stages of the new menstrual cycle 8 – 12 
antral follicles are stimulated by FSH in the ovaries. As the follicles proliferate they develop 
the ability to release oestrogen, one of two ovarian sex hormones; the second, 
progesterone, is secreted from the corpus luteum that forms from the ruptured follicle in 
the luteal phase of menstruation (Bray et al., 2005). Alongside the secretion of oestrogen 
and progesterone, inhibin A and B are also secreted from within the ovaries. Inhibin A is 
derived from the pre-ovulatory follicle, whereas inhibin B is the product of the pool of 
growing follicles (Guyton & Hall, 2006; Lund, 2008; Sievert, 2006; Woods & Mitchell, 2004). 
Together their primary function is to down regulate the synthesis of FSH and inhibit 
subsequent secretion. The cyclic nature of menstruation relies upon the complex feedback 
loops of the ovarian hormones to ensure the female body is conditioned for reproduction. 
 
The follicular phase incorporates everything from menses, referred to as Day One, to 
ovulation, which generally occurs around Day Fourteen of the cycle. During menstruation 
the low levels of oestrogen and progesterone allow the production of FSH to peak during 
the first few days of the new cycle. During this increase, the pool of antral follicles compete 
against each other until the follicle releasing the highest concentration of inhibin A, thereby 
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inhibiting further development of the remaining follicles, becomes the pre-ovulatory follicle. 
As this follicle continues to develop, increasing amounts of oestrogen and inhibin A are 
produced (Bray et al., 2005; Burger, Dudley, Robertson, & Dennerstein, 2002; Sievert, 2006). 
The increasing concentration of oestrogen acts on the uterus, stimulating regeneration and 
growth of endometrial remnants left after the previous menstrual cycle (Bray et al., 2005; 
Guyton & Hall, 2006). The rise in oestrogen also induces a mid cycle LH surge which triggers 
ovulation (Burger et al., 2007). The luteal phase follows ovulation and encompasses 
everything from this point to menses. Oestrogen continues to promote proliferative activity 
in the endometrium, while under the action of progesterone, the endometrial glands 
become primed for implantation. If implantation does not occur, the corpus luteum 
regresses, there is a rapid fall in the secretion of oestrogen and progesterone and the 
endometrium enters a state of ischemia, precipitating the onset of menses (Guyton & Hall, 
2006; Huether & McCance, 2008).  
 
The hormonal alterations that occur in response to the depleting antral follicle pool can be 
seen as early as the fourth decade (Lund, 2008; MacNaughton, Banah, McCloud, Hee, & 
Burger, 1992; Santoro, Brown, Adel, & Skurnick, 1996; Woods & Mitchell, 2004). It has been 
theorised that both inhibin A and B plays a significant role in the initial endocrine changes 
that occur prior to menopause (Burger et al., 2002; Lund, 2008). As the number of follicles 
diminishes, the concentrations of inhibin’s decrease, weakening the complex negative feed-
back loop that forms part of the mechanism controlling the concentration of FSH (Guyton & 
Hall, 2006; Lund, 2008; MacNaughton et al., 1992; Santoro et al., 1996). This results in a 
higher than usual FSH concentration, thereby stimulation of the pre-ovulatory follicle 
continues, preserving normal levels of serum oestrogen through the early stages of 
menopause (Lund, 2008). As ovulation ceases, the levels of inhibin A fall, reflecting the lack 
of a pre-ovulatory follicle available for stimulation. It is at this point that the concentration 
of oestrogen falls, thus even higher levels of FSH result. Further to this, progesterone levels 
remain low throughout the cycle since there is no corpus luteum in an anovulatory cycle. 
These physiological mechanisms underpin the natural shift from regular cycles of ovulation 
and menstruation towards permanent infertility. 
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Stages of Menopause 
In 2001 the Stages of Reproductive Aging Workshop (STRAW) was held by the North 
American Menopause Society to develop a staging system for late reproductive function. 
Perimenopause was split into two phases: early and late. A woman was deemed to be in the 
early phase when the length of her menstrual cycle changed by seven days or more but 
menses were still occurring regularly (McKinlay, 1996; Soules et al., 2001). The late phase 
was characterised by two skipped menstrual cycles and at least one intermenstrual interval 
of 60 days or more. (Soules et al., 2001). The mean age of onset for perimenopause is 
reported to be between 45.5 and 47.5 years (Burger et al., 2002; McKinlay, 1996) with an 
average duration of 4 years (Burger et al., 2002). However, these parameters vary 
considerably between women. Many women find it difficult to pinpoint their final menstrual 
period (FMP) as a result of the indefinite time period over which perimenopause can occur 
and the possibility of long-term irregularity and amenorrhoea (Burger et al., 2007; McKinlay, 
1996).  
Risks associated with early or late menopause 
As life expectancy increases, the factors that influence the average age at which women 
begin menopause have become important. This is mainly due to the number of 
postmenopausal health problems that can arise when menopause is reached outside of the 
normal range. Early onset of menopause results in premature exposure to low oestrogen 
levels leading to a greater incidence of cardiovascular disease and osteoporosis (Gallagher, 
2007; Rossouw et al., 2002). Hu et al. (1999) reported that women who begin menopause 
before the age of 50 years incur a risk of cardiovascular disease that is 38% higher than 
women who begin menopause after this age. Further to this, each year that menopause is 
postponed, it has been estimated that there is a 2% fall in the mortality due to 
cardiovascular disease (Hu et al., 1999; Parente, Faerstein, Celeste, & Werneck, 2008; van 
der Schouw, van der Graaf, Steyerberg, Eijkemans, & Banga, 1996). Similarly, premature 
exposure to decreased oestrogen can lower bone density therefore resulting in  higher 
fracture rates and an increase in the prevalence of osteoporosis (Gallagher, 2007). Although 
there are clear adverse health consequences associated with early menopause, later 
menopause is also linked with negative health ramifications. McPherson, Steel and Dixon 
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(2000) suggest that mammary cells proliferate in response to prolonged exposure to 
oestrogen, possibly leading to hyperplastic changes and the increased risk of developing 
breast cancer (Clemons & Goss, 2001). Ovarian and uterine cells are thought to be affected 
by the same mechanism, however there is little more than anecdotal evidence based on 
clinical observation to support this theory. The relationship between cardiovascular disease 
and early menopause is strongly evident (Hu et al., 1999), more so than that of the 
relationship between breast cancer and late menopause. However, as yet there is 
insufficient evidence to evaluate the relative risk associated with the occurrence of 
menopause onset.  
Factors Influencing the Onset of Menopause 
Several factors have been implicated in influencing the age of menopause, including 
smoking, obesity, alcohol consumption, socio-economic status, later menarche, long 
menstrual cycles, multiparity and the use of oral contraceptive (Chang et al., 2007; Dvornyk 
et al., 2006; Kato et al., 1998; Lawlor, Ebrahim, & Smith, 2003; Wise, Krieger, Zierler, & 
Harlow, 2002). Smoking, alcohol consumption and obesity are the most heavily researched 
of these and investigations into the remaining factors are sparse and variable.  
 
Smoking 
One of the strongest and most clearly demonstrated factors influencing age at menopause 
is cigarette smoking. Evidence consistently suggests women who smoke during the 
transitional period reach menopause 1-2 years earlier than non-smokers (Harlow & 
Signorello, 2000; Kinney, Kline, & Levin, 2006; Mikkelsen, Graff-Iversen, Sundby, & 
Bjertness, 2007; Parente et al., 2008; van Asselt et al., 2004). Despite this, there is 
uncertainty in the literature about the relative effects of past smoking, smoking doses and 
duration of smoking.  
 
It is postulated that tobacco smoke contains polycylic hydrocarbons that may be toxic to 
ovarian germ cells. Subsequently this may lead to oestrogen deficiency related to follicular 
exhaustion and the consequent increase in FSH due to diminishing inhibin levels (Harlow & 
Signorello, 2000; Parente et al., 2008; van Asselt et al., 2004). Moreover, alkaloid 
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components of tobacco smoke, including nicotine and anabasine, may have a metabolic 
effect, lowering oestrogen levels by interfering with the pathways involved in synthesis 
(Harlow & Signorello, 2000). Cigarette smoke constituents are thought to inhibit granulosa 
cell aromatase and other key enzymes in oestrogen synthesis, with the result of reducing 
oestrogen production in-situ. The effect of ovarian destruction would still be present even if 
a woman had stopped smoking before she transitioned to menopause, whereas an effect 
resulting from altered oestrogen synthesis would occur only if she was currently smoking. 
 
The literature identifies no clear relationship between a history of smoking and the age at 
which menopause occurs. Kinney et al. (2006) proposed that age of menopause among 
former smokers is comparable to that among women who never smoked. Mikkelsen et al. 
(2007) furthered this idea suggesting that cigarette smoking has to have ceased 10 years 
prior to menopause to considerably reduce the risk of early onset. In contrast to these 
hypotheses, it could be assumed that a history of smoking would have a substantial effect 
on age of menopause if there was a permanent loss of ovarian follicles, as has been 
theorised to result from cigarette use (Harlow & Signorello, 2000; Parente et al., 2008). It is 
possible that follicles of younger women are more resistant to the effects of smoking and 
that early cessation of smoking prevents substantial loss of ovarian germ cells. There is, 
however, no evidence to substantiate this claim. Alternatively, it might be that the more 
temporary metabolic effect of cigarettes in current smokers has a much greater effect on 
the levels of oestrogen compared to the influence of past ovarian germ cell destruction. Van 
Asselt et al. (2004) apparently favour this latter explanation and have stated that smoking at 
the time of perimenopause is much more important than smoking history in explaining an 
earlier onset of menopause. There is insufficient knowledge surrounding the interaction 
between the constituents of tobacco and the female reproduction organs to determine 
which of these mechanisms is the dominant factor. It is likely that a combination of 
permanent ovarian germ cell destruction, and the continued alteration in oestrogen 
synthesis occurring in current smokers is the reason for the proposed effect of age in 
perimenopausal women.   
 
There is a significant amount of literature that supports the relationship between current 
smoking and early menopause, however there is little known about the effect of dose and 
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duration. Kinney et al. (2006) reported that women who were classified as heavy smokers, 
defined as smoking 14 or more cigarettes per day at the time of their final menstrual period, 
were likely to experience menopause 2.8 [95% Confidence Interval -4.8 – -0.8] years earlier 
than non smoking women. Further to this, Mikkelsen (2007) conducted a population based, 
cross-sectional study that included a sub sample of 2,123 postmenopausal women born 
between 1940 and 1941. The results showed that total exposure to smoking (calculated as 
the product of the number of cigarettes per day and the length of time as a smoker) was 
positively related to early menopause and, at the highest doses, nearly doubled the odds of 
early onset. In a subsequent systematic review of the relationship between smoking and age 
at menopause, Parente (2008) concluded that there was insubstantial evidence to draw a 
conclusion on the relationship between the two variables and age at menopause. It is 
unknown why the studies conducted by Mikkelesen et al. and Kinney et al. were not 
included in the review; however the conflicting evidence illustrates the requirement for 
further research to be undertaken to provide definitive results.  
 
Alcohol Consumption 
Compared with the interest in smoking, few studies have examined the consumption of 
alcohol in relation to age at menopause. Alcohol consumption increases levels of plasma 
oestrogen in pre- and postmenopausal women (Gill, 2000). With respect to postmenopausal 
women, Katsouyanni, Boyle and Trichopoulous (1991), Hankinson et al. (1995) and Nagata 
Kabuto, Takatsuka and Shimizu (1997) have all reported a positive association between 
alcohol and oestrogen levels. The largest of these studies, Katsouyanni et al. noted that 
urinary oestrogen levels increased by 20% in response to a daily intake of one standard 
drink. Kinney et al. (2006) collected extensive data pertaining to the amount and frequency 
of alcohol consumption. The estimated age at natural menopause was 2.2 [95% CI 0.5 – 3.9] 
years later for women who drank alcohol 5 – 7 days per week when compared to women 
who drank no alcohol (Kinney et al., 2006). When results were analysed in terms of standard 
drinks per week, women who fell into the higher consumption bracket on average reached 
natural menopause 2.9 [95% CI 0.2 – 5.5] years later than women who drank no alcohol 
(Kinney et al., 2006). The findings from the latter study are consistent with the smaller 
studies (Mikkelsen et al., 2007; Torgerson, Thomas, Campbell, & Reid, 1997) without the 
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absence of key methodological and statistical information. Despite this, further research 
needs to be undertaken to reproduce and corroborate the research reported by Kinney et 
al.   
 
Obesity 
Obesity is considered to be an independent factor not only affecting general mortality and 
morbidity, but also inducing early onset menopause and aggravating related symptoms 
(Mastorakos & Paltoglou, 2009). Menopause is associated with the redistribution of adipose 
tissue, leading to increased abdominal fat stores and increased risk of chronic illness (Teede, 
Lombard, & Deeks, 2010). It is commonly accepted that obese women have increased 
peripheral conversion of androstenedione to oestrogen and that this, combined with a 
reduction in the circulating sex hormone-binding globulin, leads to an overall increase in the 
bioavailable oestrogen (Harlow & Signorello, 2000; Kato et al., 1998; Morris & Currie, 2010). 
Body size and fat distribution have been analysed in relation to age at menopause, as it is 
hypothesised that the hormonal and metabolic changes associated with obesity may 
contribute to a delay in the onset of menopause (Hardy, Mishra, & Kuh, 2008). Results from 
general population studies however have been inconsistent, showing either no association 
(Do et al., 1998) nor that heavier women have a later menopause (Kato et al., 1998).   
 
In a large longitudinal study analysing 5,961 Australian female twins aged 17 – 88 years for 
potential predictors of age at natural menopause, Do et. al (1998) reported no relationship 
between level of obesity and onset of menopause when analysing the entire cohort.  
Despite reporting this finding there was insufficient numerical information included in the 
report to determine the size of this effect. In a prospective study, Kato et. al. (1998) 
analysed data from the New York University Women’s Study, in which 4,694 premenopausal 
women aged between 34 – 61 years were followed for an average of 5.4 years. Compared 
with women in the lowest quintile of body mass index, the relative risks for the third, fourth 
and fifth quintiles were 0.99, 0.88 and 0.87 respectively. Conclusions were drawn that the 
more estrogenic environment associated with female obesity delayed the onset of 
menopause by several years (Kato et al., 1998). Furthermore, it is claimed that extreme 
leanness resulting from serious illness or excessive exercise combined with relative dietary 
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restriction, can suppress ovarian function resulting in the early onset of menopause (Kato et 
al., 1998). In addition, due to the limited numerical reporting, there was a lack of advanced 
statistical correction that would have been required to account for confounders such as 
other medical problems or current medications. It is conceivable that the effect of obesity 
on age at menopause is not direct, but comes about through a range of factors not always 
accounted for in statistical analysis. Additional research into the effect of obesity on age at 
menopause is required, especially given the health problems that can stem from later 
menopausal onset. Determining the importance of the relationship could be imperative to 
managing the onset and symptoms of menopause (Rachoń & Teede, 2010), particularly in 
light of the global obesity epidemic. 
Symptoms 
Perimenopausal women experience a variety of symptoms which can be broadly grouped 
into vasomotor, sexual, physical or psychological complaints (Rahman et al., 2010). Common 
symptoms include, but are not limited to: hot flushes, night sweats, joint pain, muscle 
tension, panic attacks, headaches/migraines, fatigue and depression (Cleary & Fox, 1994; 
McKinlay, 1996; Rahman et al., 2010). Symptoms associated with menopause are thought to 
escalate in the lead up to a women’s FMP. Irrespective of their severity, they can be 
disabling, affecting a women’s social life, psychological health, sense of well-being and 
ability to work (Bruce & Rymer, 2009). 
 
Vasomotor Symptoms 
Hot flushes, sweating and night sweats are cumulatively termed vasomotor symptoms and 
are commonly discussed between patient and physician. They are a major cause of reduced 
quality of life in a large percentage of perimenopausal women, but, as they are not fatal and 
generally subside of their own accord, there has been little research or clinical interest 
(Sturdee, 2008). The impact of hot flushes, in particular, on quality of life is considerable and 
often underestimated. Flushing may regularly interfere with work and daily activities, as well 
as sleep, causing insomnia, fatigue, loss of concentration, decrease in output, and 
depression, all of which can interfere with family and personal relationships (Andrikoula & 
Prelevic, 2009; Freedman, 1998; Sturdee, 2008). There are considerable differences in the 
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severity of vasomotor symptoms reported in different countries and among different races. 
In Europe and North America, the hot flush is reported as the most common symptom of 
menopause, affecting around 70% of women and persisting on average for 2 – 5 years, 
although some 20% continue to flush into their seventies and eighties (Andrikoula & 
Prelevic, 2009). By comparison, they are a relatively unreported symptom in Japanese 
populations, affecting between 5-18% women (Andrikoula & Prelevic, 2009; Freeman & 
Sherif, 2007). Given the large disparity between European and Asian cultures it is difficult to 
determine whether the lower rates of reporting in Asian countries is because they do not 
suffer from them or they do not consider it culturally acceptable to discuss it. 
 
The physiology of the menopausal hot flush is poorly understood. Given their systemic 
nature, they are likely to arise from an alteration in the central nervous system 
thermoregulatory set-point located in the anterior portion of the hypothalamus. Changes in 
core body temperature are recognised in the thermoregulatory centre, which controls 
physiological reponses that either conserve or dissipate heat (Stearns et al., 2002). In non-
symptomatic women core temperature is maintained by balancing heat production from 
metabolism and heat loss via sweating and cutaneous vasodilation, or heat conservation by 
cutaneous vasoconstriction (Freedman, 1998). In premenopausal women the threshold 
between shivering and sweating is wide, however, as women begin to go through 
menopause this threshold narrows (Stearns et al., 2002). As a result of an external trigger, 
such as a change in ambient temperature, immediate changes in hormones lead to the 
sensation of a hot flush (Stearns et al., 2002). The trigger initiates a series of heat loss 
mechanisms, including cutaneous vasodilation, flushing and sweating, which cause a slight 
drop in core temperature and relief from symptoms (Stearns et al., 2002). It is not known 
what causes the alteration in the thermoregulatory set-point, although it is thought to be 
mediated by the change in plasma oestrogen concentrations as women progress through 
menopause (Andrikoula & Prelevic, 2009; Sturdee, 2008). Oestrogen levels are known to 
decline throughout menopause and women with low circulating concentrations of 
oestrogen are more likely to be subjected to hot flushes (Stearns et al., 2002). However, 
oestrogen levels remain low throughout menopause and the frequency of hot flushes 
generally subsides throughout this transition. Moreover, according to Sturdee (2008), young 
women with ovarian dysgenesis, a congenital condition resulting in the malfunction of the 
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ovaries, never have hot flushes despite very low levels of oestrogen. Thus, it may be that the 
initial drop in oestrogen is responsible for the narrowed thermoregulatory set-point, which 
through other biochemical changes such as the altered concentrations of gonadotropins and 
neurotransitters, remains reduced for the duration of the transition (Stearns et al., 2002). 
The limited understanding surrounding the aetiology of vasomotor symptoms renders them 
difficult to alleviate in perimenopausal women.  
 
Sexual Symptoms  
Sexual function is a complex, integrated phenomenon that reflects the health and 
coordination not only of the ovaries and hormones, but also of the cardiovascular system, 
the brain, the spinal cord and the peripheral nerves (Alan, 2004; Levin & Riley, 2007). The 
stability of a women’s relationship with sexual partners, attitudes toward sex and aging, 
vaginal dryness, and cultural background have a much greater impact on sexual functioning 
than menopause itself (Northrup, 2006). Women often report change in sexual desire, a loss 
of libido or vaginal dryness during menopause; however, given the multitude of interlinking 
factors that contribute to healthy sexual function, it is a difficult area to assess. Vaginal 
dryness is thought to be the most common sexual symptom that occurs as a direct result of 
lower oestrogen levels (Bruce & Rymer, 2009; Ogurlu et al., 2010). The vagina is rich in 
oestrogen receptors, and a decline in oestrogen levels through the menopause transition 
can lead to a loss of elasticity, vascularity and adiposity in this region (Sievert, 2006). As a 
result, midlife women report painful sexual intercourse more often than younger women 
(Northrup, 2006; Sievert, 2006). Women who are not having sexual relations may not 
necessarily notice a change however, dryness can also lead to irritation, burning sensations 
and more urinary tract infections (Sievert, 2006). Given the highly personal and multi-
factorial nature of sexual related symptoms they are often only reported to health 
practitioners once they reach an unmanageable level. 
 
Musculoskeletal Symptoms 
Women experience symptoms such as joint aches and pains, headaches and general 
stiffness at many times during their lives, not only during menopause. Wood and Mitchell 
(2005) suggest that the prevalence of these symptoms increases from 41% in late 
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reproductive stage, to 47% throughout the early menopause transition and to 53% at in late 
menopause (Woods & Mitchell, 2005). This increase could be attributed solely to the aging 
process, but with the physiological changes occurring at this time it is likely that both 
menopause and increasing age contribute to the increase in symptoms. Osteoarthritis (OA), 
described as internal degeneration of the joint surfaces as a result of lifetime wear and tear, 
is a significant determinant of joint and muscle pain in the aging population, especially 
women (Gallagher, 2007). It is postulated that oestrogen deficiency plays a role in initiating 
or accelerating the degenerative process, however its specific effect is not known (Magliano, 
2010). Treatment of OA with HRT has produced conflicting results on cartilage degradation 
and repair, which may stem from the various definitions of OA and the varied prescriptions 
of HRT utilised (Birchfield, 2001; Magliano, 2010). As a result women taking HRT have shown 
both lower (Soules et al., 2001) and higher (von Mühlen, Morton, von Mühlen, & Barrett-
Connor, 2002) incidences of OA and osteoporotic fractures, particularly of the hip. Apart 
from the potential role of declining oestrogen, another possibility to explain the marked 
prevalence of musculoskeletal complaints through perimenopause is that these symptoms 
are manageable until they are combined with other perimenopausal factors and symptoms. 
 
Psychological Symptoms 
Bruce and Rymer (2009) suggest that there is a higher incidence of depressive illnesses in 
women than in men, and these are exacerbated during midlife. It is well known that 
physiologically unstable endocrine periods in life such as puberty, pregnancy, the postnatal 
period, the premenstrual phase and menopause, are associated with an increased likelihood 
of developing depressive tendencies (Birkhäuser, 2002). Common symptoms include but are 
not limited to feeling “blue”, loss of memory, irritability, poor concentration, tiredness and 
loss of self-confidence (Bruce & Rymer, 2009). A bio-cultural perspective suggests that 
although there a number of oestrogen, progesterone and testosterone receptors in the 
brain (Bruce & Rymer, 2009; Guyton & Hall, 2006), cultural context provides unique 
pressure and concerns that contributes to the risk of depression among women undergoing 
the menopausal transition. Many women throughout the Western world are dealing 
simultaneously with persistent hot flushes, concerns about adolescent children, 
responsibility for aging parents, daily stresses and financial pressures (Birkhäuser, 2002; 
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Northrup, 2006; Sievert, 2006). The onset of depressive illness during midlife cannot be 
clearly attributed to menopause alone, however the combination of hormonal changes and 
non-endocrine risk factors common during this phase are likely to be the cause of 
exacerbated symptoms (Judd, Hickey, & Bryant, 2012). Given the diversity of symptoms, and 
the complex, multi-factorial aetiology, effective treatment has yet to be determined. 
Conventional Treatment 
Hormone Replacement Therapy (HRT) 
Oestrogen products to ameliorate or eliminate symptoms of menopause such hot flushes 
and night sweats, vaginal dryness and atrophy were first approved by the Food and Drug 
Administration in 1941. Several studies have shown that oestrogen and combined 
oestrogen-progesterone therapies reduced vasomotor symptoms and vaginal complaints by 
up to 77% [95% CI 58 – 88] relative to a placebo (MacLennan, Lester, & Moore, 2001). 
However, there is limited research to suggest that HRT has the same degree of benefit on 
musculoskeletal and depressive symptoms associated with menopause. Positive effects of 
HRT on musculoskeletal symptoms were found in an Australian study of 2,130 
postmenopausal women, of whom 63% complained of joint ache and muscle pain at study 
entry. After one year of treatment the proportion of women experiencing joint pain 
decreased to 57% in women allocated to combined HRT, but stayed the same in the placebo 
group (Welton et al., 2008). These results followed an intervention period of 12 months and 
medication was only given to those women suffering from concurrent severe vasomotor 
symptoms. Similarly, the effects of HRT on depressive symptoms are contradictory. 
Randomised controlled trials investigating the effect of HRT on depressive symptoms in 
perimenopausal women without a current diagnosis of depression, have reported both 
reduced scores for measures of depressive symptoms (Yaffe, Sawaya, Lieberburg, & Grady, 
1998) and no effect on mood (van Duijn, 1996). Further research needs to be conducted to 
determine the safety and effectiveness of HRT in a cohort of women suffering from 
musculoskeletal complaints in the absence of vasomotor symptoms. Moreover, the role HRT 
plays in alleviating depressive symptoms needs to be further investigated. 
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HRT has generated significant controversy in the 60-plus years since it was FDA approved. In 
the late 1970’s oestrogen given alone was found to increase the risk of uterine cancer due 
to its proliferative action (Cabot, 2005; Grady, Gebretsadik, Kerlikowske, Ernster, & Petitti, 
1995; Rossouw et al., 2002; Smith, Prentice, Thompson, & Herrmann, 1975; Ziel & Finkle, 
1975). Synthetic progesterone was thereafter combined with oestrogen to decrease the risk 
in women with a uterus. Although in avoiding HRT-induced uterine cancer new dangers 
were uncovered, namely, increased risk of breast and ovarian cancers, cardiovascular 
disease and blood clots (Rossouw et al., 2002).   
 
Risks of Hormone Replacement Therapy 
In 1992 the Women’s Health Initiative (WHI), developed a multi-arm study which sought to 
compare the effectiveness of postmenopausal HRT, diet modification and vitamin 
supplements on heart disease, hip fractures, breast and colorectal cancers (Rossouw et al., 
2002). The hormone trial had two arms; the oestrogen-alone study of women without a 
uterus and the oestrogen-plus-progesterone study of women with a uterus. In the combined 
hormone trial 16,608 healthy postmenopausal women were recruited from 40 clinical 
centres around America and randomised into a treatment (n=8,506) or placebo group 
(n=8,102). The planned duration of the study was 8.5 years however in 2002, 5.2 years into 
the study, the trial was stopped following a recommendation from the data and safety 
monitoring board (Rossouw et al., 2002). This recommendation arose primarily because 
analysis showed that the incidence of coronary heart disease, invasive breast cancer, stroke 
and pulmonary embolism were not counter-balanced by the small reductions in hip 
fractures and colorectal cancers  (Rossouw et al., 2002).   
 
The Million Women Study was a national study of more than one million British women 
aged 50 and over (Beral, Bull, Green, & Reeves, 2007). It was a collaborative project which 
saw Cancer Research UK and the National Health Service work together to answer many 
questions about the factors affecting women’s health in this age group. One aspect of the 
study investigated the relationship between specific types of cancer, in particular ovarian 
and breast, and HRT. Postmenopausal women (n=948,576) with no previous cancer or 
history of hysterectomy were included in the analyses. Of these women 50% had used HRT 
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at some stage throughout their transition and 30% were still current users (Beral et al., 
2007). The average follow up was 5.3 years per woman for incidence of ovarian cancer and 
6.9 years for death. Current users of HRT were 1.20 times [95% CI 1.09 – 1.32] more likely to 
develop ovarian cancer and 1.23 [95% CI 1.09 – 1.38] times more likely to die from it than 
non-users of HRT (Beral et al., 2007). In women who were current users of HRT, the risk of 
ovarian cancer was greater with increasing duration of use, but did not vary according to the 
hormonal constituents, the mode of administration, or the type of HRT regime (Beral et al., 
2007). Women who developed ovarian cancer were diagnosed on an average of 2.4 years 
after the date that HRT use was last reported (Beral et al., 2007). The results corroborated 
findings of previous studies (Bosetti et al., 2001; Folsom, Anderson, & Ross, 2004; Risch, 
1996) although there is limited scope to draw comparison because past studies included 
relatively few women within their cohorts who used HRT and subsequently developed 
ovarian cancer.  
 
As with the risk of ovarian cancer, prior to the Million Women Study little was known about 
the relationship between HRT use and the incidence of breast cancer. Participants 
(n=1,084,110) aged between 50 – 64 years, provided information about their HRT use and 
were followed up for cancer incidence and death. There were 9,364 cases of invasive breast 
cancers  reported after a follow-up period of 2.5 years and 637 deaths reported after a total 
follow up period of 4.1 years (Million Women Study Collaborators, 2003). Current users 
of HRT at recruitment were 1.7 times [95% CI 1.6 – 1.8] more likely than those who had 
never used HRT to develop breast cancer and 1.2 [95% CI 1.0 – 1.5] times more likely to die 
from it (Million Women Study Collaborators, 2003). Past users of HRT were, however, not at 
an increased risk of incident or fatal disease compared to those who has never used it 
(Million Women Study Collaborators, 2003).  The Million Women Study Collaborators (2003) 
reported further data that suggested that the risk of breast cancer was greater in those 
women that use combined hormone therapy than those who use oestrogen-only 
formulations.  This finding has since been corroborated by large cohort studies completed 
following the initial results of the Million Women Study (Beral, Reeves, Bull, & Green, 2011; 
Reeves, Beral, Green, Gathani, & Bull, 2006).  
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Rossouw et al. (2002) highlighted that the WHI only tested one drug regime in the target 
population and the results did not necessarily apply to lower dosages of these drugs, other 
formulations of oral oestrogen and progesterone, or to oestrogens and progesterone 
administered through the transdermal route. Despite these limitations, the results from the 
WHI study and those from the Million Women Study provided the first definitive data on the 
long-term effects of HRT. In the wake of these findings, long term HRT has been supplanted 
by shorter courses of HRT to control perimenopausal symptoms. The oestrogen-stimulated 
endometrium still requires protection during the limited duration of HRT, thus the addition 
of progesterone is considered to be mandatory (Leonetti, Landes, Steinberg, & Anasti, 2005; 
Leonetti, Longo, & Anasti, 1999). Successful HRT depends upon the safety of the prescribed 
medication, patient acceptance and adherence. One of the main factors for reduced 
adherence is the potential for short-term systemic side effects often caused by the 
progesterone element of the medication. Symptoms commonly attributed to progesterone 
range from fluid retention, to adverse effects on skin, breast tenderness, bloating, atypical 
uterine bleeding and perception of weight gain, although it should be noted that these 
symptoms can and do occur in women who are taking oestrogen-only medications  
(MacLennan et al., 2001; Panay & Studd, 1997).   
 
Transdermal application of progesterone-based creams for the treatment of 
perimenopausal complaints and endometrial protection has not been readily studied until 
recently in light of the systemic side effects caused by oral formulations of HRT. Leonetti et 
al. (1999) completed a double-blind, placebo-controlled trial that evaluated the 
effectiveness of transdermal progesterone cream on hot flushes and bone density. While 
83% of the treatment group, compared to 19% of the placebo participants, reported 
improvement or resolution of hot flushes, the number of women showing a gain in bone 
mineral density exceeding 1.2% did not differ (Leonetti et al., 1999). Many of the women 
reported the application of vaginal medication uncomfortable and time consuming. Leonetti 
et al. (2005) subsequently completed a cross-over study that investigated the acceptance 
and endometrial effects of combined HRT compared to transdermal progesterone cream. 
Results indicated that there was a negligible difference in post-treatment endometrial 
biopsies, and 75% of women stated their preference for progesterone cream as opposed to 
the combined HRT, reporting a marked difference in systemic side effects (Leonetti et al., 
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2005). Further research is necessary before the efficacy of progesterone creams in the 
treatment of menopause-related symptoms can be objectively determined. They are 
however beneficial when used in conjunction with oestrogen-based treatment to provide 
endometrial protection as the degree of systemic side effects is reduced (Leonetti et al., 
2005). In spite of this, many women are tending to favour intrauterine systems, in which a 
long-acting, reversible hormonal contraceptive device is placed within the uterus. The local 
release of progesterone from these appears to further reduce systemic side effects and the 
system provides a high-level contraception (Leonetti et al., 2005; Leonetti et al., 1999; 
MacLennan et al., 2001). 
 
Despite the likely efficacy of HRT for the treatment of vasomotor symptoms, the negative 
connotations now associated with HRT following the WHI and the Million Women study 
have resulted in women seeking alternative treatments in a bid to alleviate symptoms 
associated with menopause. 
Alternative Treatment 
Complementary and Alternative Medicine (CAM) has been defined as “a group of diverse 
medical and health care systems, practices and products that are not presently considered 
to be part of conventional medicine” (Kessel & Kronenberg, 2004, p. 717). Despite this 
seemingly straightforward definition there is controversy over what is considered a CAM 
and what is considered conventional medicine. Interest in CAMs for the treatment of 
perimenopausal symptoms has increased markedly, particularly in the last few years 
following the results from the WHI and the Million Women Study.  Therapies such as 
bioidentical hormones, acupuncture, exercise therapy, homeopathy, meditation and 
osteopathy may help to alleviate symptoms; however there is little scientific literature that 
supports their safety and efficacy for the treatment of menopausal symptoms. The most 
researched non pharmacological therapies include acupuncture and exercise therapy (Kessel 
& Kronenberg, 2004; Rees, 2006, 2009); investigations into other therapies such as 
meditation and homeopathy are limited and unreliable.  
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Bioidentical Hormones 
A hormone is said to be bioidentical if it has exactly the same molecular structure as a 
hormone produced naturally in the human body (Cabot, 2005). Derived from plants, 
bioidentical oestrogen cannot be distinguished from its natural counterpart produced in the 
ovaries. Similarly, standard laboratory tests are unable to distinguish these and reflect the 
total oestrogen concentration including the bioidentical hormone as well as oestrogen 
produced in-situ. On the other hand, many HRTs are metabolized into various forms of 
oestrogen that are not measured by these laboratory tests. Proponents of bioidentical 
hormones contend that one advantage of bioidentical oestrogen over conventional 
treatments is that oestrogen levels can be monitored more precisely and treatment 
individualized accordingly (Northrup, 2006). This is countered with the argument that 
knowing precise levels hardly matters because it is extremely difficult to know what 
hormone level to target and symptoms, not levels, should be treated and monitored 
(Bosarge & Freeman, 2009; Files, Ko, & Pruthi, 2011).  
 
Bioidentical HRT is used in the USA, UK, and New Zealand by alternative health care 
practitioners for the treatment of symptoms of menopause, with the prevailing assumption 
that bioidentical HRT provides the benefits of conventional HRT while attenuating the risks 
(Curcio, Wollner, Schmidt, & Kim, 2006). As these custom preparations are individually 
created depending on the needs of the patient there is no guarantee of efficacy, safety or 
consistency (Chervenak, 2009; Curcio et al., 2006). These preparations can vary in their 
ingredients and dosages from patient to patient. Moreover, the formulations can vary by 
batch and by pharmacist, and the patient may not get consistent or constant amounts of 
hormones. Despite these potential downfalls, the promising nature of this treatment 
approach lacks sufficient data from well-designed comparative trials to support its safety or 
efficacy (Bosarge & Freeman, 2009). Therefore, promotion of the therapy is based on 
anecdotal evidence which raises ethical questions about the potential for false and 
misleading claims relating to bioidentical HRT (Bosarge & Freeman, 2009; Chervenak, 2009). 
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Acupuncture 
Traditional Chinese Medicine acupuncture has long been advocated for the treatment of 
gynaecological problems (Proctor et al., 2002), including those related to perimenopause 
(Northrup, 2006). The insertion of fine needles into the skin and underlying tissues has been 
shown to excite mechanoreceptors which, through interactions with serotonin and 
endorphins, alter outgoing signalling (Proctor et al., 2002).  Several randomised controlled 
trials have shown consistent results regarding the efficacy for acupuncture on reducing 
vasomotor symptoms in peri- and postmenopausal women (Borud & White, 2010; Cho & 
Whang, 2009; Lee, Shin, & Ernst, 2009). In a recent multi-centred randomised controlled 
trial both peri- and postmenopausal women were allocated into two groups: acupuncture 
plus usual care (n=116) and usual care alone (n=59) (Kim et al., 2010). The constituents of 
usual care were not described, but women taking HRT were excluded from the study (Kim et 
al., 2010). The treatment group received 12 acupuncture sessions and maintained usual care 
for four weeks, while the control group underwent usual care alone. Kim et al. (2010) 
reported a 62% reduction in the frequency and severity of hot flushes in the treatment 
group compared to a 27% reduction in the usual-care group indicating that acupuncture 
may be an effective alternative treatment for women who wish to avoid pharmaceutical 
products to control the symptoms. Earlier studies reported similar results but small sample 
sizes and poor design of placebo control render their results invalid when compared to the 
Kim et al. study. 
 
Another recent study, the ‘Acupuncture on Hot Flushes Among Menopausal Women’ study 
was a multicenter, randomised controlled trial, conducted in 2006 and 2007 (Borud, Alraek, 
White, & Grimsgaard, 2010). Participants were postmenopausal women (n=267) 
experiencing, on average, seven or more hot flushes per 24 hours. Of these women 134 
were randomised to acupuncture combined with self care and received 10 individualised 
Traditional Chinese Medicine acupuncture treatment sessions over 12 weeks. The  
remaining 133 participants were allocated to the control group and received only advice on 
self-care (Borud et al., 2010). A one-page leaflet contained information about self-care 
strategies such as stress management and regular sleep patterns, to relieve menopause 
symptoms, and study participants were free to use any of these. Broud et. al. (2007) 
reported results that illustrated the short term reduction in the frequency of hot flushes, 
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from 12.6 per 24 hours to 3.7 in the treatment group and 5.8 in the control group. Hot flush 
intensity also decreased by 3.2 units per day in the acupuncture group and 1.8 units in the 
control group (Borud et al., 2010). These results were no longer present at 6- and 12-month 
follow ups. The authors concluded that acupuncture can contribute to a more rapid 
reduction in vasomotor symptoms and therefore increase quality of life in postmenopausal 
women with no likely long-term effects (Borud et al., 2010). Despite these promising results, 
many women avoid acupuncture because of the perceived pain and fear associated with 
placing needles into the body (Proctor et al., 2002), thus may not choose this therapy for 
perimenopausal symptoms. 
Exercise Therapy 
Exercise has long been known for its positive effects on general health but has only recently 
been implicated in providing benefit for women suffering from perimenopausal complaints. 
Regular activity is thought to reduce vasomotor symptoms, mood swings and sleep 
disturbances and increase cardiovascular and musculoskeletal health (Ağıl, Abıke, Daşkapan, 
Alaca, & Tüzün, 2010; Lindh-Åstrand, Nedstrand, Wyon, & Hammar, 2004). Lindh-Astrand et 
al. (2004) used a Single System Design to determine if regular physical exercise or oral 
oestrogen therapy decreased vasomotor symptoms and increased the quality of life in 
previously sedentary post menopausal women. Participants were randomised to either the 
oral oestrogen therapy (15), or exercise (10) groups. The duration of the study was 12 weeks 
and participants in the latter group completed 3 hours of aerobic exercise per week. In the 
exercise group the frequency of hot flushes decreased from 5.1 (Standard Deviation 2.8) 
flushes per 24 hours to 3.8 per 24 hours (SD 3.0), a reduction of approximately one third, 
while in the oestrogen group flushes reduced from 8.3 (SD 3.1) per 24 hours to 0.8 (SD 1.2) 
per 24 hours. The most significant limitation of this study is that the exercise intervention 
was poorly defined, stating that the intensity of exercise had to be of a level that caused the 
participant to shower following activity. A more well defined definition and adequate 
control over participants exercise habits would render more valid data. In more recent 
research Ağıl et al. (2010) also used a Single System Design to investigate whether the 
presence of menopausal symptoms was influenced by different types of exercise. 
Participants were randomised into aerobic (15) and resistance groups (15) and exercised 3 
days per week for 8 weeks under the supervision of a physiotherapist (Ağıl et al., 2010). 
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Overall there was a large reduction in the frequency of hot flushes but there was little 
difference detected when comparing the effect sizes of the aerobic (0.14) and resistance 
(0.54) exercise programmes. The most notable difference between the aerobic and 
resistance groups was found in the effect sizes of the physical domain, 0.78 and 0.49 
respectively. Despite the promising nature of these preliminary results, further research 
utilising randomised controlled trials needs to be conducted to determine the true effect of 
exercise on menopausal related symptoms. 
 
Osteopathic Manual Therapy (OMT)  
In 1884 Andrew Taylor Still coined the term Osteopathy. It is derived from two Greek words; 
‘osteon’ meaning ‘bone’, and ‘pathos’ meaning ‘suffering’ (Parsons & Marcer, 2006).  Whilst 
there is no stringent definition for osteopathy, it is widely accepted that the principles that 
underpin diagnosis and treatment emphasise the structural and functional integrity of the 
body. Osteopathy is “distinguished by the fact that it recognises that much pain and 
disability stems from abnormalities in the function of the body structure as well as damage 
caused to it by disease” (Parsons & Marcer, 2006, p. 5). To date only one study has 
investigated the efficacy of osteopathy for treatment of symptoms related to menopause.  
 
Cleary and Fox (1994) conducted a study that aimed to investigate the effect of “Fox’s low-
force” osteopathic technique on 30 subjects with menopausal symptoms. The treatment 
group (n=15) received “Fox’s low-force” technique to joint restrictions in the spine. A finger 
or thumb was used to deliver a low force to the joint in a direction that would relieve the 
apparent movement restriction. This technique is proposed by Fox to relax the joint’s 
protective mechanism, via the muscle spindle, by increasing the length of the muscle, 
thereby improving mobility and neurological function (Cleary & Fox, 1994). The results 
showed that change in the treatment group between Week 1 and Week 10 was greater than 
the control group for the average symptoms score (p = 0.005). This study is unlikely to be 
reproduced as “Fox’s low-force” techniques are a relatively unknown technique in 
osteopathy. In this study, the control group received the same technique as the treatment 
group, the difference being it was applied to an adjacent spinal segment. The assumption 
that this placebo treatment would have no effect goes against the holistic philosophies that 
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define osteopathy as delivering the technique, albeit to a non-dysfunction segment which 
may have some underlying effect. A further limitation is that there was no practitioner 
blinding, particularly relevant in this study because the author was the founder of the 
techniques used in the study, and may have thus had a greater bias in collection and 
interpretation of results. Despite the limitation of this study, the results that arose indicate 
osteopathy as a possible modality for the treatment of perimenopausal symptoms. Further 
research needs to be conducted in order to determine the effectiveness and safety of 
osteopathy on the treatment of the often debilitating symptoms of perimenopause. 
Conclusions 
Apart from insubstantial anecdotal evidence, there is little reliable research surrounding the 
efficacy of OMT in the treatment of perimenopause. This is true of most research pertaining 
to the effectiveness and safety of common alternative therapies. HRT remains as the 
pharmaceutical treatment of choice, however many women are seeking alternative forms of 
relief following the results  and publicity that arose from the WHI and Million Women 
studies. Therefore, further investigation needs to be undertaken to determine the effect of 
these alternative treatments, specifically osteopathy, so they can be safely used and 
promoted within this cohort of women.  
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Abstract 
Background: The onset of perimenopause is a significant life event for a woman, carrying 
with it physical, medical, psychosocial and cultural significance. An estimated 85% of women 
report recurring symptoms that occur in the transition to menopause.  
 
Objective: To determine if Osteopathic Manual Therapy delivered over four weeks is an 
effective modality for treating symptoms associated with perimenopause. 
 
Methods: Six participants experiencing perimenopausal symptoms received four 
osteopathic treatments. Baseline and follow-up measures included the Menopause Quality 
of Life Questionnaire, the Greene Climacteric Scale and a Hot Flush Dairy in which 
participants recorded the frequency and intensity of any flushes. A follow up interview was 
also undertaken to gather information regarding their thoughts and experiences throughout 
the course of the treatments. 
 
Results: The frequency and severity of perimenopausal complaints exhibited substantial and 
rapid reductions. Changes in the physical (p < 0.005) and psychological (p = 0.007) domains 
of the Menopause Quality of Life Questionnaire, along with the somatic (p < 0.006), anxiety 
(p = 0.013) and vasomotor (p < 0.025) domains of the Greene Climacteric Scale attained 
statistical significance. Communication, Overall Wellbeing and Lack of Knowledge arose as 
the key themes following qualitative analyses of the follow up interviews.  
 
Conclusions: The results of this study indicate that Osteopathic Manual Therapy may be an 
effective modality for the reduction of perimenopausal symptoms. Further to this study, 
randomised controlled trials with greater participant numbers will help to provide more 
conclusive data about the possible benefit of this therapy for women experiencing 
perimenopausal symptoms.     
 
Key words: Complementary and alternative medicine, menopause, osteopathy, hot flushes, 
menopause symptoms. 
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Introduction 
Menopause is a normal physiological process that is experienced by women passing into 
midlife. The World Health Organisation defines menopause as  “the permanent cessation of 
menstruation for 12 months or more” (World Health Organisation Scientific Group, 1996, p. 
12). The physiological process of menopause, although not entirely understood, is well 
documented. From around 45 years of age only a small number of ovarian follicles remain to 
be stimulated and the production of female sex hormones decreases as the number of 
follicles approaches zero. The resulting hypogondal state may cause symptoms and 
detrimental changes in oestrogen target tissues, including the brain, skeleton, skin and the 
cardiovascular and genitourinary systems (Collins, 2006). An estimated 85% of women 
report at least one symptom throughout their transition, most notably hot flushes (Bruce & 
Rymer, 2009; Dennerstein et al., 1993; McKinlay, 1996; Woods & Mitchell, 2005). The often 
severe and debilitating nature of these symptoms are reported to effect attendance, 
concentration and output at work, as well as influencing one’s social life, psychological 
health and sense of well-being (Ogurlu, Küçük, & Aksu, 2010). The inevitable physiological 
transition necessitates an effective treatment regime, despite the unknown aetiological 
factors influencing this midlife change. 
 
Hormone Replacement Therapy (HRT) has been used to ameliorate or eliminate symptoms 
of menopause for over 70 years (Northrup, 2006). Multiple studies have illustrated the 
beneficial effect HRT has on reducing symptoms arising from oestrogen depletion, namely 
vasomotor complaints, vaginal dryness and atrophy (Collins, 2006; MacLennan, Lester, & 
Moore, 2001). The effect of HRT on other common perimenopausal symptoms such as joint 
pain and depressive tendencies is less clear (Birkhäuser, 2002; Judd, Hickey, & Bryant, 2012; 
Magliano, 2010). Although HRT provides short-term benefits and improves quality of life, 
long-term use is associated with increased risk of a number of chronic diseases. The 
Women’s Health Initiative and the Million Women Study were among the first to produce 
data pertaining to the long term effect of HRT. Preliminary analysis of the WHI data showed 
that incidence of coronary heart disease, invasive breast cancer, stroke and pulmonary 
embolism in HRT users was not counter-balanced by the small reductions in hip fractures 
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and colorectal cancers  (Rossouw, Anderson, & Prentice, 2002). Similarly, the Million 
Women Study found that the incidence of breast and ovarian cancer significantly increased 
in women who had previously used HRT (Beral, Bull, Green, & Reeves, 2007; Million Women 
Study Collaborators, 2003). 
 
In the wake of these results there is evidence that practitioners and patients alike are 
seeking an effective and safe, non-pharmaceutical therapy to combat the symptoms 
associated with menopause. Complementary and Alternative Medicines (CAMs) such as 
bioidentical hormones, acupuncture, exercise therapy and osteopathy are being increasingly 
utilised  in order to combat symptoms associated with the transitional period (Kessel & 
Kronenberg, 2004). This trend has been occurring despite a lack of definitive data 
supporting the effectiveness of these therapies in the treatment of perimenopausal 
symptoms. The primary aim of this study was to determine the effectiveness of Osteopathic 
Manual Therapy as a treatment for perimenopausal symptoms in a clinical setting. To 
achieve this, the study comprised two parts. The first part quantified changes in symptoms 
following an 8-week intervention. Following this a second qualitative component was 
formulated to explore participants’ thoughts and experiences during the intervention study.  
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Methods 
Design 
This exploratory study employed a mixed-methods design utilising an A-B-C Single System 
Research Design (SSRD) and post-hoc Interpretive Description. SSRD designs are thought to 
be especially useful for evaluating the effectiveness of interventions when they are novel or 
when the clinical presentations are widely variable (Riddoch, 1991). Interpretive Description 
examines a clinical phenomenon with the goal of identifying themes and patterns among 
subjective perspectives, while also accounting for variation between individuals (Hunt, 
2009). Schneider, Whitehead, Elliott, Lobiondo-Wood and Harber (2004) suggest that 
completing qualitative analyses after quantitative data have been collected is a valid 
approach to qualitative research and offers a means for making research more meaningful, 
complete and purposeful than when utilising a single method.  
 
 
 
 
 
 
  
50 
 
Participants 
Participants were initially recruited for the quantitative part of the study via a research 
advertising website www.getparticipants.com and secondly, as a result of snowball sampling. 
Women between the ages of 45 – 55 years in early or late perimenopause according to the 
Stages of Reproductive Aging Workshop (Soules et al., 2001) with perimenopausal 
symptoms were eligible. Women were excluded from the study if they were currently using 
HRT or hormone based contraception, or had done so in the preceding six months, had 
undergone a full hysterectomy, exhibited any contraindications to osteopathic manual 
therapy (OMT)  or if they had received OMT in the previous six months.  
 
Women who registered an interest were then sent an eligibility questionnaire [Appendix A] 
along with an information sheet [Appendix B] explaining the study.  If they were eligible to 
participate the primary researcher made contact to confirm their willingness and to address 
any concerns they may have had in relation to the study. They were then asked to sign a 
consent form [Appendix C]. Ethical approval for this research was granted by the Unitec 
Research Ethics Committee (UREC 2011-1173) on the 28/6/2011 for data collection until the 
28/6/2012 [Appendix D]. 
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Quantitative Study: Investigation Measurements 
Measurements of symptoms were recorded during a 2-week pre-intervention phase; a 4-
week intervention phase and a 2-week post-intervention phase (see Figure 1). 
 
During the 2-week pre-intervention phase participants completed the self-administered 
Menopause Quality of Life Questionnaire (MENoQL) and the Greene Climacteric Scale. 
MENoQl measurements were recorded fortnightly encompassing the previous two weeks 
and the Greene Climacteric Scale was completed weekly in respect to the previous 24 hours.  
In addition participants were asked to record each hot flush and rate its intensity as mild, 
moderate or severe. 
 
The Menopause Quality of Life Questionnaire (MENoQL)  
The MENoQL [Appendix E) is a 29-item, self-administered questionnaire developed by 
Hilditch et al. (1996) to measure the quality of life in menopausal women by assessing the 
frequency and severity of menopause-related symptoms. The questionnaire has been 
validated against established research instruments such as the Kupperman Menopausal 
Index derived from clinical experiences in the 1950s (Kupperman, Blatt, Wiesbader, & Filler, 
1953). The symptoms are divided into four domains: vasomotor, psychological, physical, 
sexual. Each question score ranges from 0-6 (from “not bothered at all” to”extremely 
bothered”) and the mean score of each domain is used as the overall subscale score.  
 
The Greene Climacteric Scale 
The Greene Climacteric Scale [Appendix F] is intended to be a brief measure of core 
perimenopausal symptoms or complaints (Greene, 1998). The scale yields four main 
independent symptom domains: vasomotor, somatic, depression and anxiety, but does not 
consider the effect of the symptoms on quality of life (Greene, 1998). Like the MENoQL, the 
Greene Climacteric Scale is self-administered; however it has only 21 items and is specific to 
the symptoms suffered by the participant in the last 24 hours rather than the last fortnight.   
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Hot Flush Frequency and Intensity 
Participants were asked to record, in a provided diary [Appendix G], the occurrence and 
severity of each hot flush, categorisng it as mild, moderate or severe.  A mild hot flush was a 
warm sensation without sweating which did not disrupt activity; moderate was a warm 
sensation (with or without sweating) which had a transient and insignificant impact on the 
participant’s activity and severe was a hot sensation with sweating that significantly 
disrupted the patients activity (Huang, Nir, Chen, Schnyer, & Manber, 2006; Utian, Shoupe, 
Bachmann, Pinkerton, & Pickar, 2001; Venzke, Calvert, & Gilbertson, 2010). Participants 
were asked to separate hot flushes that occurred during the day or wakeful period from 
those that occurred during the nocturnal sleep period (Huang et al., 2006). 
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Development of the OMT Intervention  
As there was little published research on the treatment of perimenopausal symptoms with 
OMT prior to the intervention, four interviews were held with experienced practitioners (5 
years or more in practice). Each practitioner was asked to determine what five structural 
techniques they would use if a woman with perimenopausal symptoms presented to them. 
From this information, a semi-standardised treatment protocol [Appendix H] was 
developed, similar to the one used in Fryer, Alvizator and Lamaro (2005). This allowed the 
philosophies of osteopathic medicine to be maintained whilst maintaining a degree of 
consistency in the treatments that each participant received.  
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Intervention 
During the intervention phase, participants attended four, weekly consultations (on the 
same weekday at the same time each week), in which they received osteopathic treatment 
relating specifically to their main perimenopausal complaint. Two Osteopathic student 
practitioners who were currently enrolled in the Master of Osteopathy programme at 
Unitec New Zealand, and who both signed non-disclosure forms [Appendix I,] performed the 
treatments. Each student practitioner was supervised by clinic tutors who currently held an 
annual practicing certificate in New Zealand. 
 
The initial session was 90 minutes and included a comprehensive case history as per 
standard clinical practice. During this initial session detailed information pertaining to 
reproductive health was collected using the Female Reproductive History [Appendix J] form. 
Subsequent osteopathic sessions were up to 45 minutes in duration.  
 
The treatment protocol given to practitioners focused on addressing somatic dysfunctions in 
the lumbar, thoracic and cervical spine, as well as soft tissues adjacent to these areas. 
Techniques were explained according to descriptions given in Ward (2003) and Hartman 
(2001).  In order to best address the person’s needs the practitioner aimed to discover and 
assist those locations in the body where the homeostatic, or self-correcting mechanisms, 
were most impeded.  
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Week one 
 
•Greene Climacteric Scale 
•Daily log of hot flush severity and frequency 
Week two 
•Greene Climacteric Scale 
•Daily log of hot flush severity and frequency 
Week three 
•90 minute inital osteopathic consulation 
•MENoQL Questionnaire 
•Greene Climacteric Scale 
•Daily log of hot flush severity and frequency 
Week four 
•45 minute osteopathic treatment 
•Greene Climacteric Scale 
•Daily log of hot flush severity and frequency 
Week five 
•45 minute osteopathic treatment 
•Greene Climacteric Scale 
•MENoQL Questionnaire 
•Daily log of hot flush severity and frequency 
Week six  
•45 minute osteopathic treatment 
•Greene Climacteric Scale 
•Daily log of hot flush severity and frequency 
Week 7 
•Greene Climacteric Scale 
•MENoQL Questionnaire 
•Daily log of hot flush severity and frequency 
Week 8 
•Greene Climacteric Scale 
•Daily log of hot flush severity and frequency 
Week 9 
•MENoQL Questionnaire 
 
 
 
Figure 1. The procedure during the pre-intervention, intervention and post-
intervention phases across the study. The last MENoQL questionnaire was given to 
participants at the beginning of the ninth week and applied to the two previous weeks.  No 
other outcomes measures were retested at this time. 
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Data Analysis – Quantitative Data 
Data from the MENoQL Questionnaire and the Greene Climacteric Scale were collected 
using www.surveymonkey.com, an online collection and analysis website, and then 
downloaded and tabulated into an Excel 2007 spreadsheet. Data pertaining to the 
frequency and intensity of hot flushes was manually loaded into Excel 2007.  Statistical 
analyses was completed using SPSS version 18 (SPSS, IBM, Armonk, New York).  Differences 
in measurement indices between pre-intervention, intervention and post-intervention 
phases were analysed using Repeated Measures Analysis of Variance (ANOVA) and 
Bonferroni post-hoc pair-wise comparisons. 
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Qualitative Study 
The qualitative aspect of the study was not included in the initial ethical approval, thus 
secondary approval was sought. Participants were automatically eligible to take part in this 
aspect of the study following their participation in the quantitative investigation.  
 
A second information sheet explaining the details of the interview was sent out by email 
[Appendix K]. UREC decided that written consent in an email would suffice for requirements 
of informed consent given the participants had finished their treatments. On giving their 
consent, a suitable time was arranged with participants to conduct the interview.  At the 
beginning of the interview, each participant was reminded that what they were about to say 
would be recorded. This gave them one final opportunity to withdraw if they were not 
happy to be recorded.   
 
The interview followed a semi-structured guideline of questions, although care was taken to 
ensure that questioning was open-ended so as to modulate interviewer bias and, to allow 
the participant to describe their experience. 
 
The digital audio recordings of the interviews were transferred on to the computer in an 
MP3 format so they could be transcribed verbatim using Digital Voice Editor, an audio 
transcription programme. Once all the interviews had been transcribed, each transcript was 
emailed back to the relevant participant. This allowed participants to ensure what they said 
was a true and correct representation of their thoughts and experiences. If this was not the 
case, participants were able to edit the transcript where necessary. This step helped to 
avoid misinterpretation, adding strength to this aspect of the study (Cresswell, 2007).   
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Data Analysis – Qualitative Data 
Thematic analysis was chosen to analyse the semi-structured interviews in keeping with the 
exploratory nature of the research (Cresswell, 2007). The transcripts were read repeatedly 
prior to categorising, coding and creating links (Thorne, Kirkham, & MacDonald-Emes, 1997). 
Each interview was compared to the others to establish overall themes. The overarching 
themes were then compared to the results from analysis of outcome measures used in 
quantitative study.  
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Results 
Six women took part in the quantitative investigation and their characteristics are presented 
in Table 1. Four of these women (Participants 2, 3, 4, 5) then went on to take part in the 
qualitative aspect of the research.   
 
Quantitative Results 
Overall, the largest effect sizes for change, calculated as (Post-Intervention Score – Pre-
Intervention Score) / Pre-Intervention Standard Deviation), were noted for the MENoQL 
vasomotor domain as well as the psychological, sexual and vasomotor domains in the 
Greene Climacteric Scale (range = 3.5 – 5.7). Intermediate effects were noted the 
musculoskeletal domains in both outcome measures (range = 2.5 – 3.0) and smaller effects 
for Greene Climacteric Scale anxiety and depression domains (range = 0.3 – 1.0; Table 2).  
 
Differences in the MENoQL score between the pre-intervention, intervention and post-
intervention stages of the study were found for both the physical (Figure 2; p < 0.0005) and 
the psychological domains (Figure 3; p = 0.007), but not for the vasomotor or sexual 
domains (data not shown). Post-hoc pairwise comparisons showed that the pre-intervention 
physical domain score (Figure 2) was different from both the intervention (p = 0.004) and 
post-intervention phases (p = 0.007). Differences between pre-intervention and 
intervention scores for the psychological domain reached borderline post-hoc pairwise 
significance (Figure 3; p = 0.05).  
 
Differences in the Greene Climacteric Scale for the somatic (p < 0.006; Figure 4), vasomotor 
(p = 0.013; Figure 5) and anxiety (p = 0.005; Figure 6) domains all reached statistical 
significance, whilst the sexual domain did not (data not shown). Post-hoc pairwise 
comparisons of scores among phases for the somatic domain showed differences between 
pre- and post-intervention (p = 0.025). Differences in scores between phases for the 
vasomotor and anxiety domains did not attain post-hoc pairwise significance. 
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Data collected via the hot flush diary showed between-stage differences in the intensity 
(Figure 8; p = 0.02) and a trend for this in the frequency (Figure 7; p = 0.05) of flushes. 
Percentage changes from pre- to post-intervention averaged 37.2% and 62.2% respectively. 
Neither of these two domains attained post-hoc pairwise significance. 
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Table 1 
 
 Individual Characteristics of study population 
 
 Agea Age at 
perimenopausea 
Stage of 
Perimenopauseb 
Age at start of 
hot flushesa 
Number of 
Pregnancies 
Number of 
living 
children 
BMIc Smoker 
Participant 1 47 45 Late 46 2 2d 42.8 No 
Participant 2 48 45 Late 45 0 0 25.8 No 
Participant 3 46 44 Late 45 0 0 24.6 No 
Participant 4 54 50 Late 53 6 5 43.0 No 
Participant 5 50 39 Late 40 2 0 29.4 Yes 
Participant 6 49 45 Late 46 2 2 27.1 No 
Mean ± SD 49.0 ± 2.8 44.7 ± 3.5  45.8 ± 4.2 2 ± 2.2 1.3 ± 2.0 32.1 ± 8.5  
 
 Abbreviation: BMI, Body Mass Index 
 a Years 
 b Determined during questioning using Female Reproductive History sheet  
 c Calculated as weight in kilograms divided by the square of height in meters Kg/m2.  
 d Twins from one pregnancy
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Table 2 
Effect sizes of change in symptoms 
Symptom Domains MENoQL Greene Climacteric 
Scale 
Hot Flush Diary 
Physical 2.96* (76.7%)   
Somatic  2.48* (56.4%)  
Psychological 5.67* (32.0%)   
Anxiety  1.00* (31.9%)  
Depression  0.26 (15.0%)  
Vasomotor 3.54 (34.2%) 5.00* (38.5%)  
Sexual 5.32 (35.7%)   
Frequency   1.34 (62.2%) 
Intensity   5.81 (37.2%) 
 
Effect size was calculated as the difference in mean symptom score from pre- to post-
intervention divided by the pre-intervention standard deviation. * indicates p < 0.05. The 
difference from pre- to post-intervention expressed as a percentage of pre-intervention 
values are also included in brackets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Menopause Quality of Life Questionnaire (MENoQL). Physical domain scores 
against study phase. Pre, Int and Post represent the 2-week pre-intervention, 4-week 
intervention and 2-week post intervention phases respectively. Error bars show standard 
deviations. 
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Figure 3. Menopause Quality of Life Questionnaire (MENoQL). Psychological domain scores 
against study phase. Pre, Int and Post represent the 2-week pre-intervention, 4-week 
intervention and 2-week post intervention phases respectively.  Error bars show standard 
deviations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Greene Climacteric Scale (GCS). Somatic domain scores against study phase. Pre, 
Int 3/4, Int 5/6 and Post represent the 2 week pre-intervention phase, weeks 3 and 4 of the 
intervention phase, weeks 5 and 6 of the intervention phase and the 2 week post-
intervention phase respectively. Error bars show standard deviations. 
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Figure 5. Greene Climacteric Scale (GCS). Vasomotor domain scores against study phase. 
Pre, Int 3/4, Int 5/6 and Post represent the 2 week pre-intervention phase, weeks 3 and 4 of 
the intervention phase, weeks 5 and 6 of the intervention phase and the 2 week post-
intervention phase respectively. Error bars show standard deviations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Greene Climacteric Scale (GCS). Anxiety domain scores against study phase. Pre, 
Int 3/4, Int 5/6 and Post represent the 2 week pre-intervention phase, weeks 3 and 4 of the 
intervention phase, weeks 5 and 6 of the intervention phase and the 2 week post-
intervention phase respectively.  Error bars show standard deviations. 
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Figure 7. Hot flush frequency against study phase. Pre, Int 3/4, Int 5/6 and Post represent 
the 2 week pre-intervention phase, weeks 3 and 4 of the intervention phase, weeks 5 and 6 
of the intervention phase and the 2 week post-intervention phase respectively. Error bars 
show standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Hot flush intensity against study phase. Pre, Int 3/4, Int 5/6 and Post represent the 
2 week pre-intervention phase, weeks 3 and 4 of the intervention phase, weeks 5 and 6 of 
the intervention phase and the 2 week post-intervention phase respectively. Error bars 
show standard deviations. 
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Individual Data 
The most reported MENoQL (figure 9a) symptoms were those that fell into the physical 
domain, of which there were 16 different symptoms. Participant 4 showed the most 
dramatic decrease in physical symptoms, notable across all three phases of the study.  In 
most cases, participants stabilised following a significant decrease in symptoms during the 
early part of the intervention.  It was common to see a slight increase in symptoms during 
the post intervention phase (e.g. Participants 3 and 6). See Appendix [L] for graphs 
illustrating change in all MENoQL symptom domains for each participant. 
 
Results from the Greene Climacteric Scale (figure 9b) illustrated no obvious trend with 
respect to most reported group of symptoms.  Symptoms that fell into the anxiety domain, 
of which there were six, followed a similar trend to the MENoQL physical symptoms and 
tended to decrease followed by a stabilisation or a more gradual decrease. Participant 5 
responded differently to others, showing a slight worsening in symptoms before a decrease 
and plateau that equalled the initial baseline measure. See Appendix [M] for graphs 
illustrating change in all Greene Climacteric Scale symptom domains for each participant. 
 
Data from the hot flush diary showed a decreasing trend in the frequency of hot flushes 
(figure 10a) over the 4-week intervention period. Participants 3 and 5 showed an increase in 
the number of flushes between the pre-intervention phase and weeks three and four of the 
intervention phase. Reductions in their number of flushes were reported in the second half 
of the intervention phase; Participant 3 illustrating a sudden decrease while participant 5 
demonstrated a more gradual decrease. Only one participant reported an increase in 
frequency of flushes following the conclusion of the intervention phase. 
 
Similarly to hot flush frequency, the majority of participants experienced an initial decrease 
in the average intensity of each hot flush (figure 10b). Two participants, (1 and 3) both 
showed a slight increase before reporting a reduction in the intensity of their flushes.  In 
contrast to changes in frequency of hot flushes, 3 of the 6 participants reported that 
following the intervention phase the intensity of their hot flushes began to increase again. 
See Appendix [N] for graphs illustrating change in both the frequency and intensity of hot 
flushes for each participant. 
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Figure 9a & b. a) Menopause Quality of Life Questionnaire. Physical Domain. Pre, Int and Post represent 
the 2-week pre-intervention, 4-week intervention and 2-week post intervention phases respectively. b) 
Greene Climacteric Scale (GCS). Anxiety domain. Pre, Int 3/4, Int 5/6 and Post represent the 2 week pre-
intervention phase, weeks 3 and 4 of the intervention phase, weeks 5 and 6 of the intervention phase and 
the 2 week post-intervention phase respectively. 
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Figure 10a & b. a) Hot flush frequency against study phase.  b) Hot flush intensity against study phase. 
Pre, Int 3/4, Int 5/6 and Post represent the 2 week pre-intervention phase, weeks 3 and 4 of the 
intervention phase, weeks 5 and 6 of the intervention phase and the 2 week post-intervention phase 
respectively. 
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Qualitative Results 
The analysis of the qualitative data indicated a number of topics that were common to the 
interviews with the participants. These were grouped into three themes and two sub-
themes. 
 
The first theme, Communication, illustrated the importance of the verbal interaction 
between the patient and practitioner, especially since the majority of women were unsure 
of what osteopathy was.  Communication that was perceived to be good by the participant 
helped to reduce stress and anxiety associated with seeking treatment from a relatively 
unknown modality and, talking to a student practitioner about personal matters such as 
those relating to menopause. 
 
 “The practitioner would always ask my permission and explain what she was doing.  
 She was very polite” Participant Two - Line 79 
 
 “I loved the way the practitioner explained every single little thing she was doing.  I 
 felt like I was getting the best” Participant Four - Line 68  
 
 
The Empathic Relationship between the patient and practitioner arose as a sub-theme to 
Communication. Strong empathic communication was shown to enhance the effectiveness 
of the therapeutic relationship between the patient and practitioner. The positive 
interactions appeared to be of of key importance to the overall success of the treatments.    
 
 “She was great, we got on really well” Participant Two - Line 46  
 
“She had really good rapport with me; I trusted her totally and believed what she told 
me” Participant Four - Line 62 
 
 “I felt very safe with the practitioner and that was partly to do with the great rapport
  we had” Participant Five - Line 65 
 
 
The second theme, Overall Wellbeing, reveals the impact of the transition from pre-
menopausal to perimenopausal on both the mental and physical aspects of female 
wellbeing. Menopause as an entity does not have a distinct beginning or end thus, the 
drawn-out and unpredictable nature does produce negative outcomes for some women. 
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This theme focused on the positive ramifications that came with seeking help from an 
osteopathic practitioner. 
  
 “I’ve felt a lot more positive in my own life.  It hasn’t just affected me physically it’s 
 affected me mentally too” Participant Four - Line 131 
 
 “It made me feel like someone was really thinking about how I felt and took an 
 interest in what was happening with me”  Participant Five - Line 49 
 
 
Empowerment developed as a sub-theme of Overall Wellbeing.  It became apparent that 
optimism that stemmed from having a positive patient-practitioner relationship led to a 
change in the motivational status. The encouragement and support received from the 
practitioner enabled several participants to make positive steps in changing their lifestyle 
for the better. 
 
 “I’m now thinking about what I can do to help myself and I’ve just jointed the gym.  I 
 think exercise might help in several areas of my life” Participant Three - Line 88  
 
 “It’s just given me that zest back again to get out there and try something instead of 
 feeling sorry for myself and not wanting to do anything” Participant Three - Line 190 
 
 “I felt that someone taking an interest and giving me a little bit of information has 
 motivated me a bit more to get out and do positive things for myself” Participant Five 
 - Line 183 
 
 
The third and final theme, Lack of Knowledge, illustrated an absence of understanding of 
what osteopathy was and how it could potentially help ease perimenopausal complaints.  It 
is likely that a lack of knowledge is not only applicable to women reporting perimenopausal 
symptoms, but to members of the general public seeking osteopathic treatment.   
 
 “Having never been to an osteopath I wasn’t sure what to expect or what they did 
 and had no idea how it would help me” Participant Two – Line 67 
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Discussion 
Data from this study shows that Osteopathic Manual Therapy delivered over a four-week 
period can reduce the perceived intensity of perimenopausal complaints and improve 
psychological well-being. The greatest effects were noted for symptoms in the 
musculoskeletal and psychological domains, with smaller changes occurring in the 
vasomotor domains. Symptoms that were encompassed by the musculoskeletal domains, 
referred to as somatic in the Greene Climacteric Scale and physical in the Menopause 
Quality of Life Questionnaire, included complaints such as headaches, low back pain and 
muscle aches and pains. In the Greene Climacteric Scale psychological symptoms such as 
palpitations and crying spells, were broken into two domains, anxiety and depression 
respectively. In the Menopause Quality of Life Questionnaire there was only one domain 
that encompassed all psychological-type complaints.  
 
Improvement in musculoskeletal symptoms has been shown once before in an osteopathic 
investigation that sought to determine the effect of osteopathy on the symptoms associated 
with perimenopause. Cleary and Fox (1994) found that in a cohort of 30 menopausal 
women, physical complaints such as neck pain reduced over a 15-week period when 
compared to the control group. Menopausal-related symptoms were measured using an 
unnamed symptom questionnaire that graded symptoms from 1 to 10 (1 being no pain and 
10 being unbearable). In the treatment group, 4 participants of 8 reported a 100% reduction 
for neck pain compared to 1 participant of 6 reporting the same reduction in the control 
group (Cleary & Fox, 1994). In the current study the most noteworthy finding was in the 
physical domain of the Menopause Quality of Life Questionnaire, in which a 77% reduction 
from pre- to post-intervention was observed. It is difficult to draw direct comparisons 
between the studies as Cleary and Fox analysed symptoms individually, whereas in the 
current study symptoms were grouped into domains and examined as a whole.  
Additionally, it is difficult to tell if the reported changes in the unnamed symptom 
questionnaire used by Cleary and Fox correlates with a change in the Menopause Specific 
Quality of Life Questionnaire used in the current study. A further disparity between the 
studies is the time-frame utilised for the intervention period.  Although both studies treated 
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participants weekly, Cleary and Fox continued treatment for ten weeks (compared to four 
weeks of treatment in the current study), and reported no interim outcome data to allow 
comparison. However, the results of both osteopathic studies may have been expected as 
osteopaths readily employ mobilisation, manipulation, stretching and soft tissue techniques 
when treating musculoskeletal complaints. The primary aim in most cases is to improve 
function and rebalance homeostasis altered by the presence of dysfunctional tissue (Lucas & 
Moran, 2007).  
 
Another study that has observed changes in the physical Menopause Quality of Life 
Questionnaire domain, reported on the effects of an intervention of aerobic and resistance 
exercise. Ağıl, Abıke, Daşkapan, Alaca and Tüzün (2010) utilised a Single System Research 
Design, similar to the current study, to determine the effect of exercise on menopausal 
symptoms, psychological health and the quality of life in menopausal women across an 8-
week intervention. The aerobic exercise training was performed on a cycle ergometer 3 
times per week, under the supervision of a physiotherapist. The resistance exercise 
programme was not detailed. Ağıl et al. reported small effect sizes in both the aerobic (0.8) 
and resistance (0.5) exercise groups for changes in symptoms in the physical domain of the 
Menopause Quality of Life Questionnaire. In the current study, after four weekly 
osteopathic treatments, symptoms in the physical domain displayed an effect size of 3.0. 
The large disparity demonstrates that Osteopathic Manual Therapy provides a more 
effective treatment of the symptoms associated with menopause than exercising. Direct 
comparisons between the studies can be drawn as the same outcome measure was utilised 
and a very similar methodological process was undertaken in the current study, including 
the absence of a control group.  
 
All domains encompassing depression or anxiety based symptoms consistently displayed a 
general improving trend. The anxiety domain of the Greene Climacteric Scale and the 
psychological domain of the Menopause Quality of Life Questionnaire measure displayed 
large effect sizes (1.0 and 5.7 respectively), whereas the depression domain in the Greene 
Climacteric Scale displayed a smaller effect size which did not attain statistical significance 
(0.3; refer Table 2). 
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The relationship between functional communication and the changes in the psychological 
symptoms associated with perimenopause became evident during analysis of the qualitative 
follow-up interviews. “Communication” arose as a primary theme as many participants felt 
that verbal interaction regarding the scope of osteopathy and the process of menopause 
helped to relieve stress-related anxiety associated with the unknown. Further to this, 
compassion and understanding have been shown to exert a positive influence not only on 
the emotional health of the patient but also on symptom resolution, functional and 
physiological status and pain control (Stewart, 1995). The importance of rapport between 
the patient and practitioner was encapsulated in a sub-theme of communication, the 
“Empathetic Relationship”. Without rapport a harmonious patient-practitioner relationship 
is hard to establish and difficult to maintain (Leach, 2005). Moreover, the degree of 
responsiveness of a patient in relation to any health practitioner will ultimately depend on 
the degree of rapport established between them (Leach, 2005; Martyn, 2007). The rapport 
that developed between each participant and practitioner may have had an influence on 
their attentiveness when information or advice was being given, and their willingness to 
embrace exercise or lifestyle changes. It is not possible in the present study to separate 
patient-practitioner communication from the techniques used on each participant given the 
lack of control group. It is, however, reasonable to suggest that the encouraging 
atmosphere and relaxed settings that enabled free dialogue had a direct effect on the 
psychological and therefore, physical outcomes associated with the study. 
 
The vasomotor domain in the Greene Climacteric Scale displayed a large effect size (5.0) and 
the frequency and intensity of flushes reported in the Hot Flush Diary decreased 62% and 
37% respectively. The vasomotor domain in the Menopause Quality of Life Questionnaire, 
whilst illustrating a noteworthy effect size (3.5), did not attain statistical significance. The 
small effect size may have been because general sweating was included in the domain 
alongside hot flushes and night sweats, whereas in the Greene Climacteric Scale, only the 
latter two were represented.  
 
In a recent study, Kim et al. (2010) conducted a randomised controlled trial in which 175 
peri- or postmenopausal participants were allocated to either acupuncture plus usual care 
(n = 116) or usual care alone (n = 59) groups. Acupuncture points used in the intervention 
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were selected according to the recommendations of Traditional Chinese Medicine clinical 
experts. The primary outcome measure was the mean change in the average 24 hour hot 
flush score at week four from baseline. Hot flush scores were measured by multiplying the 
frequency by severity of hot flushes recorded in a daily dairy, similar to the one used in the 
current study. Following an intervention period of four weeks, throughout which 
participants received three treatments per week, the mean number of flushes reduced with  
an effect size of 2.4 compared to 1.9 in the control group. These effects were larger than 
those observed for frequency of flushes in the current study (1.3 following 4 osteopathic 
treatments). It is difficult to draw direct comparisons given the differences in analysis and 
outcome measures. While Kim et al. used the product of frequency and severity as the 
overall hot flush score, the current study looked at frequency and intensity of flushes as 
separate entities. Further to this, the current study observed large effect sizes for relief of 
symptoms in the vasomotor domains of both the Greene Climacteric Scale (5.0) and the 
Menopause Quality of Life Questionnaire (3.5). Kim et al. used the Menopause Rating Scale 
which has similar characteristics to the Greene Climacteric Scale but did not report data on 
the vasomotor domain. Overall, it is difficult to determine if one or other modality is more 
effective however, it is reasonable to suggest that osteopathy provides a faster and less 
invasive treatment for perimenopausal symptoms when compared to acupuncture.  
 
Even though there are distinct differences between osteopathy and acupuncture, both 
modalities aim to improve function through restoring the balance of structure within the 
body (Bonnie, 2008; Lucas & Moran, 2007). Whilst the mechanisms behind vasomotor 
symptoms are unclear it is possible that osteopathic therapy delivered to the thoracic spine 
could be advantageous to women suffering from vasomotor symptoms. The primary aim of 
treatment in this area consists of addressing hypertonicity, increasing mobility and blood 
flow. It may be that a secondary effect is that of reducing the output of the sympathetic 
ganglia. These ganglia deliver information about stress and impending danger, and are 
responsible for the fight or flight response (Craven, 2011; Waterhouse & Campbell, 2011). 
Some osteopathic authors suggest that dysfunction of the tissues in which these ganglia are 
located may increase their output because of their close proximity to their overactive 
tissues, thus leading to constant stimulation of the sympathetic nervous system (Craven, 
2011; Parsons & Marcer, 2006). This type of continuous demand on the body can lead to 
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chronic overstimulation and blunted responses to new stressors (Crockett & Panickar, 2011; 
Fisher, Young, & Fadel, 2009; McCarty, Horwatt, & Konarska, 1988). If the activity of the 
ganglia is reduced by way of manual technique, it may improve the body’s capability to deal 
with the external triggers thought to set off the cascade of events that lead to a hot flush. 
 
With only 6 participants it may be difficult to generalise the results of this study to the wider 
cohort of women going through perimenopause. The final sample size cannot be considered 
a true representation of the total population as the inclusion and exclusion criteria focused 
on a small proportion of women who were currently experiencing perimenopausal-related 
symptoms. The inclusion criteria encompassed parameters that ensured that participants 
were experiencing moderate symptoms associated with perimenopause, but the exclusion 
criteria prohibited the participation of women who were currently using HRT or hormone 
based oral contraceptives or had done so in the preceding six months. Further research is 
warranted to determine the effects of osteopathic manual therapy in conjunction with 
hormone replacement therapy or hormone based contraceptives.  
 
In the current study a Single System Research Design was employed primarily in response to 
the lack of literature surrounding the treatment of perimenopausal symptoms with 
Osteopathic Manual Therapy. However, in the absence of a control group it is not possible 
to identify the mechanism by which the perimenopausal symptoms were affected. It is 
particularly difficult to separate the verbal interaction between the patient and practitioner 
from the hands-on treatment given by the practitioner. What can be stated is that the 
overall effect of treatment reduced muscular aches and pains, muscular hypertonicity, 
vasomotor and psychological symptoms as well as increasing range of movement, all of 
which reduced stress on the neurological system. In order to uncover the specific 
mechanisms by which these reported changes occurred, further research in this field needs 
to utilise the standardised process of a randomised controlled trial. This methodology is the 
widely accepted standard in determining the efficacy of a clinical intervention, whether it be 
medicinal or physical in nature. 
 
The current study did not seek to recognise the efficacy of one single technique, but rather 
encompassed the holistic and individualised nature of osteopathy by means of a semi-
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standardised treatment protocol. Collaboration took place with registered osteopaths to 
develop a representative treatment approach for use on perimenopausal women. Each 
participant was given a treatment that focused on their primary complaint and took into 
consideration factors that contributed to their personal group of symptoms. As a result the 
internal validity associated with the study was traded-off in favour of external validity, 
treatment was thus more representative of that occurring in private osteopathic practice.     
 
There is no doubt that further research into the effect of osteopathy for women 
experiencing menopausal-related complaints needs to be conducted, primarily with larger 
scale controlled and blinded studies to confirm the results of this investigation. In addition, 
the effect of an extended treatment regime should be investigated as the initial reduction of 
somatic, psychological and vasomotor symptoms suggest that a longer intervention period 
may further reduce or completely alleviate symptoms associated with perimenopause. 
Women would be more likely to utilise osteopathic medicine for perimenopausal complaints 
if it was clear that they could obtain a similar reduction in symptoms as that associated with 
conventional treatments. Finally, the effect of the patient-practitioner relationship and 
communication on the overall well-being of perimenopausal women may provide further 
information to determine the most effective practice when treating women with 
menopausal-related symptoms.  
 
The results of this study suggest that structural osteopathic techniques, employed within 
the treatment protocol, may be an effective way of reducing physical, psychological and 
vasomotor symptoms that are common to women who are going through menopause. 
These results, although preliminary, will help to further practitioners’ knowledge 
surrounding perimenopause and may have a wider positive impact on clinical outcomes for 
women of this age group. Further research that; confirms the effectiveness of the treatment 
protocol utilised in this research, includes a control group, and establishes the longer-term 
effect of osteopathic treatment is warranted, in order to completely understand the role of 
osteopathic medicine for the treatment of symptoms associated with perimenopause. 
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(A) Eligibility Questionnaire 
Female Reproductive History – Eligibility 
 
1. How old are you? 
 
 
2. Have you had a hysterectomy         Yes        No 
  
 
2a. Were your ovaries left after the operation? 
 
 
3. Have you had hot flushes? 
  
 
3a. What age did they start? 
 
4. Have you used hormone replacement therapy since the onset of perimenopause? 
  
 
 
4a. When was the last time you took the medication? 
 
 
4b. Please list hormone preparations and the dose you are taking or have taken: 
 
Hormone Daily Dose Date Started Date Stopped 
    
    
 
5. Have you had any osteopathic treatment in the last 6 months? 
 
6. Have you had cancer? 
 If ‘YES’ please specify type, treatment and outcome 
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(B) Quantitative Information Sheet 
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(C) Quantitative Consent Form
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(D) Ethical Approval 
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(E) Menopause Quality of Life Questionnaire 
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(F) The Greene Climacteric Scale 
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(G) Hot Flush Diary 
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(H) Treatment Protocol 
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(I) Non Disclosure Form 
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(J) Female Reproductive History Form 
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(K) Qualitative Information Sheet 
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(L) MENoQL – Individual Symptom Domains  
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(M) Greene Climacteric Scale – Individual Symptom Domains 
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(N) Hot Flush Frequency and Intensity  
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